International Journal of Hypertension / 2017 / Article / Tab 2

Review Article

Hypertension Management in Brazil: Usual Practice in Primary Care—A Meta-Analysis

Table 2

Frequency of blood pressure lowering medication use, diagnostic tests, and medical appointments among hypertensive subjects.

Prevalence (95% CI)/mean (±SD)Heterogeneity
Status quo value

Blood pressure lowering medication (%)
In use of one BPLM42.7 (28.6–58.1)<0.0199.0
In use of two BPLM33.0 (23.7–43.9)<0.0192.4
Type of BPLM
Thiazide diuretics
 Single-drug therapy or combined with another drug41.1 (26.4–57.6)<0.0198.3
 Single-drug therapy18.2 (7.4–38.4)<0.0196.6
 Combined with ACEI14.9 (11.1–19.8)<0.0184.6
 Combined with BB9.4 (5.7–15.2)<0.0186.5
 Combined with 5.0 (2.4–7.6)NANA
Angiotensin-converting enzyme inhibitors (ACEI)
 Single-drug therapy or combined with another drug41.1 (20.2–65.7)<0.0197.7
 Single-drug therapy16.2 (11.6–22.1)<0.0185.0
 Combined with 3.4 (2.5–4.7)0.0762.1
 Combined with 4.0 (2.1–5.9)NANA
Beta-blockers (BB)
 Single-drug therapy or combined with other BPLM21.2 (17.3–25.8)<0.0184.3
 Single-drug 10.0 (8.1–12.3)0.1746.2
 Combined with 2.3 (0.5–4.1)NANA
Calcium channel blockers (CCB)
 Single-drug therapy or combined with other BPLM10.0 (7.5–13.3)<0.0172.4
 Single-drug 3.9 (1.6–6.2)NANA
Angiotensin receptor blockers (ARB)
 Single-drug therapy or combined with other 2.3 (1.4–3.6)0.0671.2
Diagnostic tests and procedures (%) among hypertensive subjects
Previous month testing
6.3 (3.9–8.8)NANA
 Any 9.7 (6.8–12.7)NANA
 Any urine 8.4 (5.6–11.2)NANA
 Any blood 12.6 (9.3–16.0)NANA
 Direct 35.0 (30.2–39.8)NANA
Previous 12-month testing
 Serum 19.5 (13.9–25.2)NANA
 Serum 31.0 (24.4–29.6)NANA
 Total serum 35.5 (28.7–42.3)NANA
 Serum LDL or HDL 25.0 (18.3–31.2)NANA
 Serum 34.0 (27.3–40.8)NANA
 Fasting plasma 36.5 (29.6–43.4)NANA
 Urine 25.0 (18.8–31.2)NANA
Medical appointments (%) among hypertensive subjects
 Annual mean of medical appointments2.62 (2.37)0.50
 Mostly using Brazilian Health Care 51.2 (46.1–56.2)NANA
 Mostly using private 20.9 (16.8–25.1)NANA
 Mostly using health plan 13.0 (9.6–16.4)NANA
 Mostly using emergency 1.9 (0.5–3.2)NANA
13.0 (9.6–16.4)NANA

effect analysis. on one study. the diagnosis of hypertension; LDL: low-density lipoprotein; HDL: high-density lipoprotein; value and –: nonapplicable; that is, only one study provided data; NA: not applicable.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.